PresentationWelcome, ladies and gentlemen. Welcome to the last day of JPMorgan Healthcare Conference and today's presentation from Inventiva. It's my pleasure to introduce Andrew Obenshain, CEO of Inventiva. We'll first do the presentation after that, there is time for some questions. So feel free to save those to the end.Andrew ObenshainCEO & Director Thank you very much, and thank you for having us at this conference, and thank you for ordering up some beautiful weather this week. I'm glad to see there's ...

Summary of Sichuan Kelun-Biotech Biopharmaceutical FY Conference Company Overview - **Company Name**: Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) - **Industry**: Biopharmaceuticals - **Focus Areas**: Research, development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas [2][3] Key Points Pipeline and Product Development - **Pipeline Programs**: Over 30 pipeline programs, including four approved products with seven indications, two products at NDA stage, and over 10 in clinical development [3] - **Employee Count**: Approximately 2,000 employees, with 900 in R&D, 500 in manufacturing and quality control, and 500 in sales and marketing [3] - **Approved Products**: - TROP2 ADC (SAC-TMT) approved for three indications in China, including lung cancer [4] - HER2-ADC (trastuzumab botidotecan) approved for HER2-positive breast cancer [4] - Cetuximab N01 for RAS wild-type colorectal cancer and PD-L1 for nasopharyngeal carcinoma [4] Clinical Studies and Results - **Clinical Trials**: Five pivotal studies initiated for breast cancer, six for lung cancer, and one for gastrointestinal cancer [5] - **Study Presentations**: Clinical data presented at major conferences, including ESMO and published in journals like the New England Journal of Medicine [6] - **Efficacy Data**: SAC-TMT demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in various cancer types [10] Strategic Collaborations - **Partnerships**: Collaborations with MSD, Ellipses Pharma, and others to enhance pipeline value and global market reach [7][8] - **Out-License Agreements**: Entered into agreements to develop and commercialize novel oncology therapies [8] Market Position and Future Plans - **Market Access**: Three core products included in the National Reimbursement Drug List (NRDL) effective January 2026 [7] - **Commercialization Strategy**: Full-fledged commercialization team established, focusing on Class III hospitals and key opinion leaders [6] - **Growth Plans**: Focus on advancing differentiated pipeline programs, optimizing ADC platform, and expanding capabilities for drug development and commercialization [15][16] Innovation and Technology - **OptiDC Platform**: A world-class drug-conjugate technology platform aimed at optimizing drug design for better efficacy and safety [2][13] - **Non-Oncology Applications**: Exploring ADCs for autoimmune and metabolic diseases, combining biologicals and small molecules [14][15] Additional Insights - **Market Trends**: The company is positioned to leverage its innovative drug development capabilities in a rapidly evolving biopharmaceutical landscape, particularly in oncology [2][15] - **Regulatory Environment**: The inclusion of products in the NRDL indicates a supportive regulatory environment for biopharmaceuticals in China [7] This summary encapsulates the key aspects of the conference, highlighting the company's strategic direction, product pipeline, and market positioning within the biopharmaceutical industry.

44th Annual J.P. Morgan Healthcare Conference March 2025 January 15, 2026 Ram Aiyar President and Chief Executive Officer 11 Forward-Looking Statement and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or str ...

Vanda Pharmaceuticals FY Conference Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovative therapies with a strong commercial portfolio anchored by four FDA-approved brands: Fanapt, Hetlioz, Ponvory, and Nereus [2][3] Core Products and Pipeline - **Fanapt**: An atypical antipsychotic approved for bipolar I disorder and schizophrenia. A long-acting injectable formulation is in phase three for schizophrenia, and a program for hypertension has been initiated [4][5] - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and other sleep disturbances. It is at the regulatory stage for insomnia and jet lag disorder [6][7] - **Ponvory**: Approved for relapsing forms of multiple sclerosis, with ongoing phase three programs for psoriasis and ulcerative colitis [6][7] - **Nereus**: Recently approved for motion sickness, with potential applications in GLP-1 induced nausea and vomiting, and gastroparesis [6][7][10] Financial Performance - For Q3 2025, Vanda reported revenue of $56.3 million, with contributions from Fanapt ($31 million), Hetlioz ($18 million), and Ponvory ($7 million). The company expects total revenue for 2025 to be between $210 million and $230 million [21][22] Strategic Focus - The company aims to grow and diversify revenue by expanding existing products and introducing new ones, targeting six commercial products by the end of 2026 [3][4] - Upcoming regulatory catalysts include Bysanti's PDUFA date on February 21, 2026, and the initiation of phase three programs for GLP-1 induced vomiting [7][10] Market Opportunities - **Nereus**: The motion sickness market has approximately 30% of adults in the U.S. experiencing symptoms, translating to a potential patient population of around 12 million. The GLP-1 market, valued at over $50 billion, presents a significant opportunity for Nereus as an adjunct treatment [11][12][35] - **Bysanti**: Expected to extend the psychiatry portfolio, especially with a potential indication for major depressive disorder (MDD), which could open treatment options for an additional 20 million patients [15][31] Commercialization Strategy - Vanda has a robust sales force of around 300 reps, primarily targeting psychiatrists, but plans to expand efforts to include primary care physicians for Bysanti [26][28] - The company anticipates a transition strategy from Fanapt to Bysanti, leveraging existing resources to maintain revenue streams post-Fanapt's expected loss of exclusivity around 2027 [28][29] R&D Milestones - Nereus's approval for motion sickness was a significant milestone, with a commercial launch expected in the second half of 2026. The company is also pursuing additional indications for its products [7][10] - Imsidolimab, targeting generalized pustular psoriasis, is under priority review with a potential launch in summer 2026 [17][37] Conclusion - Vanda Pharmaceuticals is positioned for significant growth with a strong pipeline and strategic focus on expanding its product offerings. The upcoming regulatory milestones and market opportunities in motion sickness and the GLP-1 space are key drivers for future revenue growth [39]

I hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug development, which I now bring into my work as an investor and analyst. For the past five years, I have been active in the investing space, with the last four years dedicated to ...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 14 best booming stocks to buy right now. On January 8, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on the stock with a share price target of $56. Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) This update is a reaffirmation of the firm’s revision on the stock on December 9, when it lifted the price target to $56 from $35 after the company shared encouraging data from the Phase 1 study of TERN-701, ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the 14 best booming stocks to buy right now. The stock is surging and has gained over 57% in the last three months, as of the close on January 12. Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 Shares closed 3% higher on Tuesday, January 13, after the company provided a corporate update and outlined its priorities for 2026. Major milestones for the current year include the expectation of top-line findings for Sevasemten by the fourth qua ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick of nearly 60%, as of the close of business on January 12. Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside However, on January 6, Wolfe Research downgraded the stock to Peer Perform from Outperform, and according to a report on TipRanks, the firm also removed its $92 price target for ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the 14 best booming stocks to buy right now. On January 12, Goldman Sachs analyst Richard Law upgraded the stock’s rating to Buy from Neutral, with a share price target of $67. Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral The adjustment followed promising results from a trial investigating the impact of atumelnant on congenital adrenal hyperplasia (CAH). The findings revealed a 67% reduction in A4 in Cohort 4, rep ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the 14 best booming stocks to buy right now, with staggering three-month returns of over 420%. Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus On January 12, Wedbush analyst Laura Chico lifted the price target on the stock to $95 from $83, citing the company’s recent public offering as the basis for the adjustment. According to a press release later during the day, the offering generated around $621 million in net pro ...